A 47-year-old woman presents to the physician with complaints of fatigue accompanied by symmetric pain, swelling, and stiffness in her wrists, fingers, knees, and other joints. She describes the stiffness as being particularly severe upon awakening, but gradually improves as she moves throughout her day. Her physician initially suggests that she take NSAIDs. However, after a few months of minimal symptomatic improvement, she is prescribed an immunosuppressive drug that has a mechanism of preventing IL-2 transcription. What is the main toxicity that the patient must be aware of with this particular class of drugs?
Q42
A 33-year-old woman with a history of multiple sclerosis is brought to the physician because of dizziness, urinary incontinence, loss of vision in her right eye, and numbness and weakness of the left leg. She has had recurrent episodes of neurological symptoms despite several changes in her medication regimen. An MRI of the brain shows several new enhancing lesions in the periventricular white matter and the brainstem. Treatment with a drug that binds to CD52 is initiated. Which of the following agents was most likely prescribed?
Q43
A 65-year-old male presents to the physician after noticing gross blood with urination. He reports that this is not associated with pain. The patient smokes 1.5 packs per day for 45 years. Dipstick analysis is positive for blood, with 5 RBC per high-power field (HPF) on urinalysis. A cystoscopy is performed, which is significant for a lesion suspicious for malignancy. A biopsy was obtained, which is suggestive of muscle-invasive transitional cell carcinoma. Before radical cystectomy is performed, the patient is started on cisplatin-based chemotherapy. Which of the following is most likely associated with this chemotherapeutic drug?
Q44
A 32-year-old woman comes to the physician with fever and malaise. For the past 2 days, she has felt fatigued and weak and has had chills. Last night, she had a temperature of 40.8°C (104.2°F). She has had a sore throat since this morning. The patient was recently diagnosed with Graves disease and started on methimazole. Laboratory studies show:
Hemoglobin 13.3 g/dL
Leukocyte count 3,200/mm3
Segmented neutrophils 8%
Basophils < 1%
Eosinophils < 1%
Lymphocytes 80%
Monocytes 11%
Platelet count 220,000/mm3
Which of the following is the most appropriate next step in management?
Q45
A 2-year-old boy is brought to his pediatrician for evaluation of a tender red big toe. His mother also notes that she has seen him recently starting to bite his own fingers and also exhibits spasms of muscle tightness. She reports that his diapers often contain the substance shown in the photograph. On exam he is noted to be significantly developmentally delayed as he is neither walking nor talking. Which of the following would be the first-line pharmacologic treatment for this patient's disorder?
Q46
A 17-year-old girl is brought into the physician's office with complaints of nausea, vomiting, headache, and blurry vision. In preparation for final exams the patient's mother started her on an array of supplements and herbal preparations given the "viral illness" that is prevalent at her school. Despite these remedies, the girl has been feeling perpetually worse, and yesterday during cheerleading practice had to sit out after vomiting and feeling dizzy. The patient admits to falling during one of the exercises and hitting her head on another girl's shin due to her dizziness. When asked to clarify her dizziness, the patient states that she feels rather lightheaded at times. The patient's BMI is 19 kg/m^2. She endorses diarrhea of recent onset, and some non-specific, diffuse pruritus of her skin which she attributes to stress from her finals. The patient has a past medical history of anxiety, depression, and excessive exercise habits. On physical exam the patient is alert and oriented to place, person, and time, and answers questions appropriately. She denies any decreased ability to participate in school or to focus. Her skin is dry and peeling with a minor yellow discoloration. Her memory is intact at 1 minute and 5 minutes for 3 objects. The patient's pupils are equal and reactive to light and there are no abnormalities upon examination of cranial nerve III, IV or VI.
Which of the following is the most likely cause of this patient's symptoms?
Q47
A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9°F (38.3°C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. A drug with which of the following mechanisms of action is most appropriate for the management of this patient?
Q48
A 3-month-old infant is brought to the emergency department because of lethargy and skin discoloration that started after he was fed some locally prepared baby food from a farmer's market. On presentation, he appears irritable and responds slowly to stimuli. Physical examination reveals rapid, labored breathing and a blue tinge to the infant's skin. A blood sample drawn for testing is found to be darker than normal. Which of the following is the most likely cause of this infant's presentation?
Q49
A previously healthy 48-year-old man comes to the physician because of a 2-month history of weight loss and yellowing of the skin. He works as a farmer and cultivates soybean and corn. He does not smoke, drink alcohol, or use illicit drugs. His vital signs are within normal limits. Physical examination shows scleral icterus and tender hepatomegaly. Ultrasonography of the abdomen shows a 5-cm nodular lesion in the right lobe of the liver. Further evaluation of the lesion confirms hepatocellular carcinoma. The activity of which of the following enzymes most likely contributed to the pathogenesis of this patient's condition?
Q50
A 66-year-old man presents to your office for a regular checkup. His only current complaint is periodic difficulty falling asleep at night. He takes captopril and hydrochlorothiazide for hypertension, atorvastatin for hyperlipidemia, and aspirin for cardiovascular disease prevention. His past medical history is significant for tympanoplasty performed 8 years ago for tympanic membrane rupture after an episode of purulent otitis media and intussusception that required surgical intervention 10 years ago. He also had a severe anaphylactic reaction after his 2nd Tdap administration 3 years ago. His blood pressure is 145/90 mm Hg, heart rate is 88/min, respiratory rate is 12/min, and temperature is 36.4°C (97.5°F). Physical examination only reveals a laterally displaced point of maximum impulse. Blood analysis shows the following findings:
Sodium: 139 mEq/L (139 mmol/L)
Potassium: 5.0 mEq/L (5.0 mmol/L)
Chloride: 100 mEq/L (100 mmol/L)
Bicarbonate: 22 mEq/L (22 mmol/L)
Albumin: 3.8 mg/dL (38 g/L)
Urea nitrogen: 8 mg/dL (2.86 mmol/L)
Creatinine: 2.1 mg/dL (0.185 mmol/L)
Uric acid: 5.8 mg/dL (0.34 mmol/L)
Calcium: 8.9 mg/dL (2.22 mmol/L)
Glucose: 106 mg/dL (5.89 mmol/L)
Total cholesterol: 254 mg/dL (5.57 mmol/L)
Low-density lipoprotein: 58 mg/dL (1.5 mmol/L)
High-density lipoprotein: 77 mg/dL (2.0 mmol/L)
Triglycerides: 159 mg/dL (1.8 mmol/L)
The patient is concerned about pneumococcal infection and has never been vaccinated against pneumococcus. He should receive pneumococcal vaccination today. Which of the following statements regarding contraindications to pneumococcal vaccination in this patient is correct?
Antimicrobials US Medical PG Practice Questions and MCQs
Question 41: A 47-year-old woman presents to the physician with complaints of fatigue accompanied by symmetric pain, swelling, and stiffness in her wrists, fingers, knees, and other joints. She describes the stiffness as being particularly severe upon awakening, but gradually improves as she moves throughout her day. Her physician initially suggests that she take NSAIDs. However, after a few months of minimal symptomatic improvement, she is prescribed an immunosuppressive drug that has a mechanism of preventing IL-2 transcription. What is the main toxicity that the patient must be aware of with this particular class of drugs?
A. Pancytopenia
B. Osteoporosis
C. Hepatotoxicity
D. Nephrotoxicity (Correct Answer)
E. Hyperglycemia
Explanation: ***Nephrotoxicity***
- The drug described, which prevents **IL-2 transcription**, is likely a **calcineurin inhibitor** like cyclosporine or tacrolimus, often used in autoimmune diseases.
- **Nephrotoxicity** (kidney damage) is a major dose-limiting toxicity of calcineurin inhibitors, causing both acute and chronic kidney injury.
*Pancytopenia*
- While some immunosuppressants can cause **pancytopenia** (e.g., azathioprine, methotrexate), it is not the classic or primary toxicity associated with calcineurin inhibitors.
- Calcineurin inhibitors primarily affect **renal function** and can cause other side effects like hypertension or neurotoxicity.
*Osteoporosis*
- **Osteoporosis** is a known side effect of long-term glucocorticoid use, but not typically a primary toxicity of calcineurin inhibitors.
- Glucocorticoids reduce bone formation and increase bone resorption, leading to bone density loss.
*Hepatotoxicity*
- **Hepatotoxicity** (liver damage) can occur with various immunosuppressants, such as methotrexate, but it is not the most prominent or defining toxicity for calcineurin inhibitors.
- While cyclosporine can cause some liver enzyme elevation, **nephrotoxicity** is far more common and severe.
*Hyperglycemia*
- **Hyperglycemia** can be a side effect of some immunosuppressants, particularly **glucocorticoids** and **tacrolimus** (another calcineurin inhibitor).
- However, for the class of drugs that prevent IL-2 transcription (calcineurin inhibitors), **nephrotoxicity** remains the most significant and common major toxicity to be aware of.
Question 42: A 33-year-old woman with a history of multiple sclerosis is brought to the physician because of dizziness, urinary incontinence, loss of vision in her right eye, and numbness and weakness of the left leg. She has had recurrent episodes of neurological symptoms despite several changes in her medication regimen. An MRI of the brain shows several new enhancing lesions in the periventricular white matter and the brainstem. Treatment with a drug that binds to CD52 is initiated. Which of the following agents was most likely prescribed?
A. Alemtuzumab (Correct Answer)
B. Eculizumab
C. Abciximab
D. Rituximab
E. Bevacizumab
Explanation: ***Alemtuzumab***
- **Alemtuzumab** is a monoclonal antibody that targets **CD52**, a glycoprotein found on the surface of mature lymphocytes (T and B cells), monocytes, and macrophages, leading to their depletion.
- It is used in **highly active relapsing-remitting multiple sclerosis (RRMS)**, especially when other disease-modifying therapies have failed, which aligns with the patient's history of recurrent neurological symptoms and new enhancing lesions.
*Eculizumab*
- **Eculizumab** targets the **C5 complement protein** and is used for conditions like **paroxysmal nocturnal hemoglobinuria** and **atypical hemolytic uremic syndrome**, not multiple sclerosis.
- It works by inhibiting the complement cascade, which is not the primary mechanism of action for MS treatment involving lymphocyte depletion.
*Abciximab*
- **Abciximab** is a **glycoprotein IIb/IIIa inhibitor** that prevents platelet aggregation and is used as an antiplatelet agent in acute coronary syndromes and percutaneous coronary intervention.
- Its mechanism of action and primary indication are unrelated to the immunological processes involved in multiple sclerosis.
*Rituximab*
- **Rituximab** targets **CD20** on B cells and is used in conditions like **non-Hodgkin lymphoma**, **chronic lymphocytic leukemia**, and certain autoimmune diseases like **rheumatoid arthritis** and **vasculitis**.
- While it's a B-cell depleting agent and has shown efficacy in MS, the question specifically asks for a drug that binds to **CD52**, not CD20.
*Bevacizumab*
- **Bevacizumab** is an anti-VEGF antibody that inhibits **angiogenesis** and is primarily used in the treatment of various cancers, such as colorectal, lung, and renal cell carcinoma.
- Its mechanism of action involving inhibition of vascular endothelial growth factor (VEGF) is not indicated for the management of multiple sclerosis.
Question 43: A 65-year-old male presents to the physician after noticing gross blood with urination. He reports that this is not associated with pain. The patient smokes 1.5 packs per day for 45 years. Dipstick analysis is positive for blood, with 5 RBC per high-power field (HPF) on urinalysis. A cystoscopy is performed, which is significant for a lesion suspicious for malignancy. A biopsy was obtained, which is suggestive of muscle-invasive transitional cell carcinoma. Before radical cystectomy is performed, the patient is started on cisplatin-based chemotherapy. Which of the following is most likely associated with this chemotherapeutic drug?
A. Cardiotoxicity
B. Hemorrhagic cystitis
C. Addition of mesna decreases drug toxicity
D. Gentamicin enhances toxicity risk (Correct Answer)
E. Myelosuppression
Explanation: ***Gentamicin enhances toxicity risk***
- **Cisplatin** is a platinum-based chemotherapeutic agent with characteristic toxicities including **nephrotoxicity** (dose-limiting), **ototoxicity**, and **peripheral neuropathy**.
- **Gentamicin** is an aminoglycoside antibiotic that is also **nephrotoxic** and **ototoxic**.
- Concurrent use of gentamicin with cisplatin significantly **enhances the risk of both nephrotoxicity and ototoxicity** due to additive effects on renal tubular cells and cochlear hair cells.
- This is a **clinically important drug-drug interaction** that must be avoided or carefully monitored.
*Myelosuppression*
- While cisplatin can cause mild myelosuppression, this is **not its most characteristic or dose-limiting toxicity**.
- **Carboplatin** (another platinum agent) is much more associated with myelosuppression than cisplatin.
- Cisplatin's hallmark toxicities are **nephrotoxicity, ototoxicity, and neurotoxicity**.
*Cardiotoxicity*
- **Cardiotoxicity** is primarily associated with **anthracyclines** (e.g., doxorubicin, daunorubicin), not cisplatin.
- Anthracyclines cause dilated cardiomyopathy through free radical damage.
*Hemorrhagic cystitis*
- **Hemorrhagic cystitis** is a well-known side effect of **cyclophosphamide** and **ifosfamide**, not cisplatin.
- This condition is caused by the metabolite **acrolein**, which irritates the bladder lining.
*Addition of mesna decreases drug toxicity*
- **Mesna** (2-mercaptoethane sulfonate sodium) is specifically used to prevent hemorrhagic cystitis caused by **cyclophosphamide** and **ifosfamide** by binding and detoxifying acrolein.
- Mesna does **not mitigate cisplatin toxicity**; cisplatin toxicity is managed with **adequate hydration and saline diuresis** to protect the kidneys.
Question 44: A 32-year-old woman comes to the physician with fever and malaise. For the past 2 days, she has felt fatigued and weak and has had chills. Last night, she had a temperature of 40.8°C (104.2°F). She has had a sore throat since this morning. The patient was recently diagnosed with Graves disease and started on methimazole. Laboratory studies show:
Hemoglobin 13.3 g/dL
Leukocyte count 3,200/mm3
Segmented neutrophils 8%
Basophils < 1%
Eosinophils < 1%
Lymphocytes 80%
Monocytes 11%
Platelet count 220,000/mm3
Which of the following is the most appropriate next step in management?
A. Discontinue methimazole (Correct Answer)
B. Switch to propylthiouracil
C. Bone marrow biopsy
D. Test for EBV, HIV, and CMV
E. Begin oral aminopenicillin
Explanation: ***Correct: Discontinue methimazole***
- This patient's symptoms (fever, sore throat, malaise) along with severe **neutropenia** (8% of 3,200/mm³ = 256/mm³) after starting methimazole indicate **drug-induced agranulocytosis**
- Agranulocytosis is a rare but serious side effect of thionamides that requires **immediate cessation** of the causative drug to prevent life-threatening infections
- This is the most urgent priority in management
*Incorrect: Switch to propylthiouracil*
- Propylthiouracil (PTU) is another thionamide that can also cause agranulocytosis
- There is risk of **cross-reactivity** between thionamides
- Switching to another thionamide is inappropriate in a patient with clear drug-induced agranulocytosis
*Incorrect: Bone marrow biopsy*
- While bone marrow biopsy would confirm lack of granulocyte precursors, it is not the most immediate next step
- The clinical picture and peripheral blood counts are already sufficiently diagnostic
- The urgent priority is **discontinuation of the offending drug**, not further diagnostic testing
*Incorrect: Test for EBV, HIV, and CMV*
- While viral infections can cause leukopenia, the specific context of recent methimazole initiation and profound neutropenia strongly suggests **drug-induced agranulocytosis**
- Testing for viruses is less urgent than addressing the suspected drug reaction
- This would be considered if drug-induced cause is ruled out
*Incorrect: Begin oral aminopenicillin*
- While the patient is at high risk of serious bacterial infection given severe neutropenia and fever, the **most appropriate initial step** is removing the causative agent
- Antibiotic therapy should be initiated promptly *after* drug discontinuation
- Treatment would typically involve **intravenous broad-spectrum antibiotics** in the hospital setting, not oral aminopenicillin
Question 45: A 2-year-old boy is brought to his pediatrician for evaluation of a tender red big toe. His mother also notes that she has seen him recently starting to bite his own fingers and also exhibits spasms of muscle tightness. She reports that his diapers often contain the substance shown in the photograph. On exam he is noted to be significantly developmentally delayed as he is neither walking nor talking. Which of the following would be the first-line pharmacologic treatment for this patient's disorder?
A. 6-mercaptopurine
B. Methionine
C. Probenecid
D. Hydroxyurea
E. Allopurinol (Correct Answer)
Explanation: **Allopurinol**
- This patient presents with symptoms highly suggestive of **Lesch-Nyhan syndrome**, an X-linked recessive disorder characterized by **HGPRT deficiency**. Key features include **gout-like symptoms** (tender red big toe, crystals in diaper), **self-mutilation** (biting fingers), **developmental delay** (not walking/talking), and **muscle spasticity**.
- Allopurinol is the **first-line pharmacologic treatment** for Lesch-Nyhan syndrome to manage the **hyperuricemia** and prevent gout and kidney stones by inhibiting **xanthine oxidase**, thereby reducing uric acid production.
*6-mercaptopurine*
- **6-mercaptopurine** is an antimetabolite primarily used in the treatment of certain cancers, particularly **leukemia**, and some autoimmune diseases.
- It is not indicated for the direct treatment of hyperuricemia or the neurological symptoms of Lesch-Nyhan syndrome.
*Methionine*
- **Methionine** is an essential amino acid and is not a primary treatment for Lesch-Nyhan syndrome or hyperuricemia.
- It is sometimes supplemented in conditions like homocystinuria, which presents differently.
*Probenecid*
- **Probenecid** is a **uricosuric agent** that increases the excretion of uric acid in the urine.
- While it lowers serum uric acid, it is generally **contraindicated in children** and in conditions with **overproduction of uric acid** (like Lesch-Nyhan) due to the increased risk of **uric acid stone formation**.
*Hydroxyurea*
- **Hydroxyurea** is an antineoplastic agent used primarily in conditions like **sickle cell anemia** and **myeloproliferative disorders**.
- It works by inhibiting DNA synthesis and is not used for the treatment of hyperuricemia or the specific manifestations of Lesch-Nyhan syndrome.
Question 46: A 17-year-old girl is brought into the physician's office with complaints of nausea, vomiting, headache, and blurry vision. In preparation for final exams the patient's mother started her on an array of supplements and herbal preparations given the "viral illness" that is prevalent at her school. Despite these remedies, the girl has been feeling perpetually worse, and yesterday during cheerleading practice had to sit out after vomiting and feeling dizzy. The patient admits to falling during one of the exercises and hitting her head on another girl's shin due to her dizziness. When asked to clarify her dizziness, the patient states that she feels rather lightheaded at times. The patient's BMI is 19 kg/m^2. She endorses diarrhea of recent onset, and some non-specific, diffuse pruritus of her skin which she attributes to stress from her finals. The patient has a past medical history of anxiety, depression, and excessive exercise habits. On physical exam the patient is alert and oriented to place, person, and time, and answers questions appropriately. She denies any decreased ability to participate in school or to focus. Her skin is dry and peeling with a minor yellow discoloration. Her memory is intact at 1 minute and 5 minutes for 3 objects. The patient's pupils are equal and reactive to light and there are no abnormalities upon examination of cranial nerve III, IV or VI.
Which of the following is the most likely cause of this patient's symptoms?
A. Idiopathic intracranial hypertension
B. Migraine headache with aura
C. Bulimia nervosa
D. Head trauma
E. Supplement use (Correct Answer)
Explanation: ***Supplement use***
- The patient's history of being started on "an array of supplements and herbal preparations" for a "viral illness," combined with **nausea, vomiting, headache, blurry vision, dizziness, diarrhea, and pruritus,** strongly suggests an adverse reaction or toxicity from these supplements.
- The **dry, peeling skin with minor yellow discoloration** could indicate vitamin A toxicity, as many "viral illness" supplements contain high doses of vitamin A, and this symptom set is highly consistent with hypervitaminosis A.
*Idiopathic intracranial hypertension*
- While idiopathic intracranial hypertension (IIH) can present with **headache, nausea, vomiting, and blurry vision**, it typically involves **papilledema** on fundoscopic exam, which is not mentioned and generally causes more severe visual disturbances than described.
- IIH is more common in **obese young women**, and this patient has a BMI of 19 kg/m^2, making it less likely.
*Migraine headache with aura*
- Migraines can cause **headache, nausea, vomiting, and aura** (e.g., blurry vision, dizziness), but the **diarrhea, pruritus, diffuse dry skin with yellow discoloration**, and the onset coinciding with supplement use are not typical features of a migraine.
- The symptoms are described as progressively worsening over time, which is less consistent with a typical migraine attack.
*Bulimia nervosa*
- The patient has a history of anxiety, depression, and excessive exercise, which can be associated with bulimia, but there is no mention of **binge-eating** or **purging behaviors** (like self-induced vomiting).
- The combination of **dry skin, yellow discoloration, diarrhea, and widespread pruritus** is not classic for bulimia nervosa, which often presents with **dental erosions, parotid gland enlargement, and electrolyte imbalances**.
*Head trauma*
- While the patient admits to falling and hitting her head, her symptoms of **nausea, vomiting, headache, blurry vision, and dizziness** predated the fall and worsened irrespective of it.
- She is **alert, oriented, answers questions appropriately, and has intact memory** with no focal neurological deficits or abnormal cranial nerve findings (III, IV, VI), making a significant head injury less likely to be the primary cause of her widespread symptoms.
Question 47: A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9°F (38.3°C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. A drug with which of the following mechanisms of action is most appropriate for the management of this patient?
A. RNA synthesis inhibitor
B. 30S ribosomal subunit inhibitor
C. Cell wall synthesis inhibitor
D. 50S ribosomal subunit inhibitor
E. Folate synthesis inhibitor (Correct Answer)
Explanation: ***Folate synthesis inhibitor***
- The patient's presentation with **persistent fevers**, **night sweats**, **productive cough**, **cavitations** on chest radiograph, and a **CD4 count of 85 cells/mm^3** in an HIV-positive individual with poor HAART adherence strongly suggests an **opportunistic infection**.
- The bronchoalveolar lavage finding of "**partially acid-fast gram-positive branching rods**" is characteristic of **Nocardia asteroides**. **Trimethoprim-sulfamethoxazole**, which inhibits folate synthesis, is the drug of choice for Nocardia infections.
*RNA synthesis inhibitor*
- This mechanism is associated with drugs like **rifampin**, which is primarily used for **Mycobacterium tuberculosis** infections.
- While tuberculosis can cause cavitations and affect HIV patients, the description of "partially acid-fast gram-positive branching rods" points away from Mycobacterium and towards Nocardia.
*30S ribosomal subunit inhibitor*
- This mechanism is characteristic of **aminoglycosides** and **tetracyclines**. While some of these drugs might have activity against certain bacteria, they are not first-line for Nocardia.
- Aminoglycosides, like amikacin, can be used as an alternative or in combination therapy for severe Nocardia infections, but trimethoprim-sulfamethoxazole is generally preferred.
*Cell wall synthesis inhibitor*
- This mechanism is typical of **beta-lactam antibiotics** (penicillins, cephalosporins) and **vancomycin**.
- Nocardia are **intracellular bacteria** and often express **beta-lactamases**, making standard cell wall inhibitors less effective as monotherapy.
*50S ribosomal subunit inhibitor*
- This mechanism is characteristic of **macrolides** (e.g., azithromycin, clarithromycin) and **clindamycin**.
- While some macrolides might have limited activity against certain Nocardia species, they are not the primary treatment for **Nocardia asteroides** infection.
Question 48: A 3-month-old infant is brought to the emergency department because of lethargy and skin discoloration that started after he was fed some locally prepared baby food from a farmer's market. On presentation, he appears irritable and responds slowly to stimuli. Physical examination reveals rapid, labored breathing and a blue tinge to the infant's skin. A blood sample drawn for testing is found to be darker than normal. Which of the following is the most likely cause of this infant's presentation?
A. Lead
B. Methanol
C. Carbon monoxide
D. Salicylates
E. Nitrates/Nitrites (Correct Answer)
Explanation: ***Nitrates/Nitrites***
- The presentation of **lethargy**, **rapid, labored breathing**, **blue skin tinge (cyanosis)**, and **darker than normal blood** in an infant after consuming food from a farmer's market is highly suggestive of **methemoglobinemia**, commonly caused by nitrate/nitrite poisoning.
- Infants are particularly susceptible to nitrates because their immature gastrointestinal tracts have higher pH and a different bacterial flora, leading to increased conversion of nitrates to nitrites, which then oxidize hemoglobin to **methemoglobin**.
*Lead*
- **Lead poisoning** typically presents with more chronic symptoms such as **abdominal pain**, **constipation**, **developmental delay**, and **anemia**, rather than acute cyanosis and rapid breathing.
- It does not cause methemoglobinemia or the characteristic dark blood associated with it.
*Methanol*
- **Methanol poisoning** usually causes severe metabolic acidosis, visual disturbances (e.g., **blindness**), and neurological symptoms, along with gastrointestinal upset; it does not directly cause cyanosis or dark blood in this manner.
- Exposure typically occurs through ingestion of contaminated alcohol or solvents.
*Carbon monoxide*
- **Carbon monoxide (CO) poisoning** causes a **cherry-red** skin discoloration, not a blue tinge, due to the formation of carboxyhemoglobin, and the blood would appear bright red, not abnormally dark.
- Symptoms include headache, nausea, dizziness, and confusion, but not methemoglobinemia.
*Salicylates*
- **Salicylate poisoning** (e.g., aspirin) leads to a mixed respiratory alkalosis and metabolic acidosis, fever, tinnitus, and hyperventilation; it does not cause cyanosis or the dark blood associated with methemoglobinemia.
- While it can cause lethargy and altered mental status, the specific presentation of blue skin and dark blood points away from salicylates.
Question 49: A previously healthy 48-year-old man comes to the physician because of a 2-month history of weight loss and yellowing of the skin. He works as a farmer and cultivates soybean and corn. He does not smoke, drink alcohol, or use illicit drugs. His vital signs are within normal limits. Physical examination shows scleral icterus and tender hepatomegaly. Ultrasonography of the abdomen shows a 5-cm nodular lesion in the right lobe of the liver. Further evaluation of the lesion confirms hepatocellular carcinoma. The activity of which of the following enzymes most likely contributed to the pathogenesis of this patient's condition?
A. Cytochrome P450 monooxygenases (Correct Answer)
B. Nuclear glycosylases
C. Lysosomal serine proteases
D. Cytosolic cysteine proteases
E. Peroxisomal catalases
Explanation: ***Cytochrome P450 monooxygenases***
- This patient, a farmer exposed to agricultural products like soybean and corn, likely developed **hepatocellular carcinoma** due to exposure to **aflatoxins**, which are common contaminants of these crops.
- **Aflatoxins** are metabolized by **hepatic cytochrome P450 monooxygenases** into highly reactive **epoxide intermediates**, which can bind to DNA and cause mutations, leading to cancer.
*Nuclear glycosylases*
- **Nuclear glycosylases** are involved in **DNA repair**, specifically in the base excision repair pathway, removing damaged or incorrect bases from DNA.
- While important for maintaining genomic integrity, their activity is not typically implicated in the initial formation of carcinogenic metabolites like those from aflatoxins.
*Lysosomal serine proteases*
- **Lysosomal serine proteases** are involved in protein degradation within lysosomes and are not directly involved in the metabolic activation of procarcinogens or the initial steps of DNA damage leading to hepatocellular carcinoma.
- Their primary role is in cellular waste management and nutrient recycling.
*Cytosolic cysteine proteases*
- **Cytosolic cysteine proteases**, such as calpains and caspases, are crucial for various cellular processes including apoptosis, but they do not typically play a direct role in the metabolic activation of procarcinogens or the genotoxic events leading to chemical-induced liver cancer.
- Their functions are generally related to protein turnover and cell signaling.
*Peroxisomal catalases*
- **Peroxisomal catalases** are enzymes primarily responsible for decomposing **hydrogen peroxide** into water and oxygen, protecting the cell from oxidative damage.
- While managing reactive oxygen species is vital, catalases are not involved in the metabolic activation of procarcinogens like aflatoxins; their role is more in detoxification of harmful byproducts.
Question 50: A 66-year-old man presents to your office for a regular checkup. His only current complaint is periodic difficulty falling asleep at night. He takes captopril and hydrochlorothiazide for hypertension, atorvastatin for hyperlipidemia, and aspirin for cardiovascular disease prevention. His past medical history is significant for tympanoplasty performed 8 years ago for tympanic membrane rupture after an episode of purulent otitis media and intussusception that required surgical intervention 10 years ago. He also had a severe anaphylactic reaction after his 2nd Tdap administration 3 years ago. His blood pressure is 145/90 mm Hg, heart rate is 88/min, respiratory rate is 12/min, and temperature is 36.4°C (97.5°F). Physical examination only reveals a laterally displaced point of maximum impulse. Blood analysis shows the following findings:
Sodium: 139 mEq/L (139 mmol/L)
Potassium: 5.0 mEq/L (5.0 mmol/L)
Chloride: 100 mEq/L (100 mmol/L)
Bicarbonate: 22 mEq/L (22 mmol/L)
Albumin: 3.8 mg/dL (38 g/L)
Urea nitrogen: 8 mg/dL (2.86 mmol/L)
Creatinine: 2.1 mg/dL (0.185 mmol/L)
Uric acid: 5.8 mg/dL (0.34 mmol/L)
Calcium: 8.9 mg/dL (2.22 mmol/L)
Glucose: 106 mg/dL (5.89 mmol/L)
Total cholesterol: 254 mg/dL (5.57 mmol/L)
Low-density lipoprotein: 58 mg/dL (1.5 mmol/L)
High-density lipoprotein: 77 mg/dL (2.0 mmol/L)
Triglycerides: 159 mg/dL (1.8 mmol/L)
The patient is concerned about pneumococcal infection and has never been vaccinated against pneumococcus. He should receive pneumococcal vaccination today. Which of the following statements regarding contraindications to pneumococcal vaccination in this patient is correct?
A. He has a severe allergy to diphtheria toxoid, a component of PCV13.
B. He is currently experiencing a moderate to severe acute illness with fever.
C. He is severely immunocompromised and cannot receive live vaccines.
D. He has a known severe allergy to any component of the PCV13 vaccine.
E. None of the above are valid contraindications to vaccination in this patient. (Correct Answer)
Explanation: ***None of the above are valid contraindications to vaccination in this patient***
This patient **should receive pneumococcal vaccination today**. The correct answer recognizes that none of the listed concerns represent true contraindications. Let's analyze why each potential concern is NOT a valid contraindication:
*He has a severe allergy to diphtheria toxoid, a component of PCV13*
- The patient had anaphylaxis to **Tdap vaccine** (contains tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis)
- **PCV13 uses CRM197 carrier protein**, a non-toxic mutant of diphtheria toxin, which is structurally different from diphtheria toxoid
- **Allergy to diphtheria toxoid does not predict allergy to CRM197** - they are different proteins with different immunogenic properties
- Clinical studies show patients with diphtheria toxoid allergy typically tolerate CRM197-conjugated vaccines safely
- This is **not a contraindication** to PCV13
*He is currently experiencing a moderate to severe acute illness with fever*
- **Temperature: 36.4°C (97.5°F) - completely afebrile and normal**
- Only complaint: periodic difficulty sleeping (not an acute illness)
- Vital signs are stable with no signs of systemic illness
- Physical exam unremarkable except displaced PMI (chronic finding from hypertension/cardiomegaly)
- **No acute illness is present** - vaccination should proceed today
- Note: Only moderate to severe acute illness with fever is a contraindication; minor illnesses are not
*He is severely immunocompromised and cannot receive live vaccines*
- This patient has **no evidence of immunocompromise** from his medical history or medications
- **Both PCV13 and PPSV23 are inactivated vaccines** - they can be safely administered to immunocompromised patients
- In fact, immunocompromised status **strengthens the indication** for pneumococcal vaccination
- This concern is irrelevant as pneumococcal vaccines are not live vaccines
*He has a known severe allergy to any component of the PCV13 vaccine*
- His Tdap anaphylaxis does not automatically indicate allergy to PCV13 components (different vaccine formulations)
- No documented allergy to specific PCV13 components (polysaccharides, CRM197, or aluminum phosphate)
- This is **not established** in this patient and therefore not a contraindication
**Correct vaccination approach:** This 66-year-old patient with chronic kidney disease (creatinine 2.1 mg/dL) and cardiovascular disease should receive pneumococcal vaccination today. Per CDC guidelines for adults ≥65 years who have never received pneumococcal vaccine: **PCV20 alone OR PCV15 followed by PPSV23** (8 weeks later for immunocompetent, 8 weeks for immunocompromised).